Morningstar's Novo Nordisk A/S Class B Stock Analysis
There is no Morningtar’s Analysis data available.
Novo Nordisk A/S Class B's Company Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Bagsvaerd, DK-2880, Denmark